Implication of HMOX1 and CCR5 genotypes on clinical phenotype of Egyptian patients with sickle cell anemia
Sickle cell disease (SCD) is a relatively common inherited hemolytic anemia among individuals of African descent. Genetic factors might clarify clinical diversity of the disease and variations in treatment response. Some researchers investigated heme oxygenase-1 (HMOX1) or chemokine receptor 5 (CCR5Δ32) genotypes among SCD patients and their correlation with fetal hemoglobin (HbF) and disease severity. However, there are no such records among Arab nations. We aimed to estimate the prevalence of the HMOX1-413 A>T (rs2071746) and CCR5Δ32 (rs333) polymorphisms, and to assess their effect on SCD phenotype and HbF level among Egyptian patients. Polymerase chain reaction assay was used to determine these polymorphisms among 100 SCD patients and 100 healthy controls. Though not statistically significant, the frequency of individual carrying HMOX-1 polymorphic AT and TT genotypes in both patient and control groups was 92% and 85% respectively. Regarding CCR5Δ32 polymorphisms, all SCD patients harbored the wild genotype (100%), while the heteromutant genotype was encountered in 2% of our controls. Patients harboring mutant HMOX-1 had a less frequent vaso-occlusive crisis (VOC)/lifetime, less VOC in the last year, less incidence of stroke, less frequency of hospitalization, and responded more frequently to hydroxyurea with statistically significant differences (p = 0.028, 0.007, 0.046, 0.007, and 0.011 respectively). No significant associations with HbF level or other hematologic parameters were encountered among our cohort. Our study results suggest a protective effect of mutant HMOX-1 genotypes in ameliorating the phenotypic severity of the disease. HMOX1-413 A>T (rs2071746) polymorphisms might prove to be a prognostic marker among Egyptian SCD, but not CCR5Δ32 (rs333) polymorphisms.
KeywordsSickle cell disease HMOX1 CCR5Δ32 Egypt
Compliance with ethical standards
The study protocol was approved by the Research Ethics Committee of Faculty of Medicine, Cairo University. Informed consents were willingly given by the parents or guardians of participants prior to enrollment in the study. All procedures performed in our study were in accordance with the 1964 Helsinki declaration.
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.Bean CJ, Boulet SL, Ellingsen D, Pyle ME, Barron-Casella EA, Casella JF, Payne AB, Driggers J, Trau HA, Yang G, Jones K (2012) Heme oxygenase-1 gene promoter polymorphism is associated with reduced incidence of acute chest syndrome among children with sickle cell disease. Blood. 120(18):3822–3828CrossRefGoogle Scholar
- 4.Serjeant GR (1992) Sickle cell disease, 2nd edn. Oxford University Press Inc, New YorkGoogle Scholar
- 11.Lopes MP, Santos MN, Faber EW, Bezerra MA, Hatzlhofer BL, Albuquerque DM, Zaccariotto TR, Ribeiro DM, Araújo AD, Costa FF, Sonati MD (2014) The CCR5Δ32 polymorphism in Brazilian patients with sickle cell disease. Dis Markers 2014:1–4. https://doi.org/10.1155/2014/678246
- 15.DÌaz F, Vega JA, PatiÒo PJ, Bedoya G, Nagles J, Villegas C, Vesga R, Rugeles MT (2000) Frequency of CCR5 ∆32 mutation in human immunodeficiency virus (HIV)-seropositive and HIV-exposed seronegative individuals and in general population of Medellin, Colombia. Mem Inst Oswaldo Cruz, Rio de Janeiro 95(2):237–242CrossRefGoogle Scholar
- 16.Hansson HH, Maretty L, Balle C, Goka BQ, Luzon E, Nkrumah FN, Schousboe ML, Rodrigues OP, Bygbjerg IC, Kurtzhals JA, Alifrangis M, Hempel C (2015) Polymorphisms in the Haem oxygenase-1promoter are not associated with severity of Plasmodium falciparum malaria in Ghanaian children. Malar J 14:153CrossRefGoogle Scholar
- 19.Nascimento AF, Oliveira JS, Junior JS, Barbosa AA (2017) Haplotypes and polymorphism in the CCR5 gene in sickle cell disease. Genet Mol Res 16(2). https://doi.org/10.4238/gmr16029675
- 21.Wagener FA, da Silva JL, Farley T, de Witte T, Kappas A, Abraham NG (1999) Differential effects of heme oxygenase isoforms on heme mediation of endothelial intracellular adhesion molecule 1 expression. J Pharmacol Exp Ther 291(1):416–423Google Scholar